Atherosclerosis Supplements : Impact Factor & More
eISSN: 1878-5050pISSN: 1567-5688
Share this on:
Key Metrics
CiteScore 
2.1
H-Index
46
SNIP
0.62
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Atherosclerosis Supplements
Atherosclerosis Supplements Journal Specifications
Indexed in the following public directories
CrossRef 
Scopus 
Web of Science
| Overview | |
| Publisher | ELSEVIER IRELAND LTD |
| Language | English |
| Frequency | Bi-monthly |
| General Details |
View less
Planning to publish in Atherosclerosis Supplements ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Atherosclerosis Supplements
Calciprotein particles disrupt autophagy in vascular endothelial cells and smooth muscle cells.
- 1 Sep 2026
- Atherosclerosis plus
Cholesterol in amyotrophic lateral sclerosis: a bystander, a biomarker, or a target?
- 1 Sep 2026
- Atherosclerosis plus
Associations of lipoprotein(a) concentrations with cardiovascular disease in men and women with primary hypercholesterolemia.
- 1 Sep 2026
- Atherosclerosis plus
LDL-cholesterol distance to target: A practical tool for guiding lipid-lowering treatment decisions.
- 1 Sep 2026
- Atherosclerosis plus
Proprotein convertase subtilisin/kexin type 9-CC-motif chemokine ligand 2 interactions link lipoprotein(a) composition to intermediate monocyte inflammation in coronary artery disease.
- 1 Sep 2026
- Atherosclerosis plus
Awareness and perceptions of systemic inflammation in atherosclerotic cardiovascular disease and chronic kidney disease: The SPARK-CVD China survey.
- 1 Sep 2026
- Atherosclerosis plus
Calciprotein particles disrupt autophagy in vascular endothelial cells and smooth muscle cells.
- 1 Sep 2026
- Atherosclerosis plus
Cholesterol in amyotrophic lateral sclerosis: a bystander, a biomarker, or a target?
- 1 Sep 2026
- Atherosclerosis plus
Associations of lipoprotein(a) concentrations with cardiovascular disease in men and women with primary hypercholesterolemia.
- 1 Sep 2026
- Atherosclerosis plus
LDL-cholesterol distance to target: A practical tool for guiding lipid-lowering treatment decisions.
- 1 Sep 2026
- Atherosclerosis plus
Proprotein convertase subtilisin/kexin type 9-CC-motif chemokine ligand 2 interactions link lipoprotein(a) composition to intermediate monocyte inflammation in coronary artery disease.
- 1 Sep 2026
- Atherosclerosis plus
Awareness and perceptions of systemic inflammation in atherosclerotic cardiovascular disease and chronic kidney disease: The SPARK-CVD China survey.
- 1 Sep 2026
- Atherosclerosis plus
FAQs on Atherosclerosis Supplements
How long has Atherosclerosis Supplements been actively publishing? 
What is the publishing frequency of Atherosclerosis Supplements?
How many articles did Atherosclerosis Supplements publish last year?
What is the eISSN & pISSN for Atherosclerosis Supplements?
What is Citescore for Atherosclerosis Supplements?
What is the H Index for Atherosclerosis Supplements ?
What is SNIP score for Atherosclerosis Supplements?
Who is the publisher of Atherosclerosis Supplements?
